Full Text View
Tabular View
No Study Results Posted
Related Studies
Lifemel Honey to Reduce Leucopenia During Chemotherapy
This study is not yet open for participant recruitment.
Study NCT00243165   Information provided by Rambam Health Care Campus
First Received: October 20, 2005   No Changes Posted

October 20, 2005
October 20, 2005
November 2005
 
Prevention of myelotoxicity-every week during chemotherapy.
Same as current
No Changes Posted
 
 
 
Lifemel Honey to Reduce Leucopenia During Chemotherapy
Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

 
Phase II
Interventional
Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Breast Cancer
Behavioral: Lifemel honey intake every day
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Not yet recruiting
60
 
 

Inclusion Criteria:

  • breast cancer patient treated with adjuvant chemotherapy
  • PS = 2 or less

Exclusion Criteria:

  • none
Female
18 Years and older
No
Contact: Georgeta Fried, MD 972-4-8543018 g_fried@rambam.health.gov.il
 
 
NCT00243165
 
LifemelCTIL
Rambam Health Care Campus
zufglobus.com
Principal Investigator: Georgeta Fried, MD Rambam Health Care Campus
Rambam Health Care Campus
October 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP